AstraZeneca Global CEO Suboko: The world needs to speed up the approval of rare disease drugs

　　China News Service, March 25. The 2024 Annual Meeting of the China Development Forum will be held on March 24-25, 2024. The "Big Health Industry Symposium" was held on the afternoon of March 24. In his speech in the "Panel Discussion One" session, AstraZeneca Global CEO Suboko said: The world needs to speed up the approval of rare disease drugs so that they can be used. Rare disease patients can benefit sooner.

　　Suboko said that technological development in the pharmaceutical industry can not only promote the health and economic development of the Chinese people, but also promote global health and economic development, mainly in the following three aspects.

The first is to support the development of relevant technologies in the pharmaceutical industry through policy support.

The Chinese government should increase policy support to allow these biopharmaceutical companies to innovate technologies and further contribute to China and the world.

The second is to use technology to achieve early treatment and screening.

On the one hand, with the continuous development of cancer screening and other technologies, the earlier the disease can be diagnosed, the sooner the patient can be helped to recover; on the other hand, the continuous development of AI technology can help the medical team to recover faster by analyzing and using a large number of databases. to develop relevant therapies.

Third, the development of innovative policies should attach great importance to international cooperation.

From early clinical trials to investment to research and development, innovative policies have evolved over the years and become increasingly important. However, today, if we want to continue to promote the development of innovative policies, such as data exchange, sampling, etc., international cooperation is particularly important.

　　Suboko pointed out that more and more people are realizing the importance of treating rare diseases. There are now 7,000 different rare diseases, and the world needs to speed up the approval of rare disease drugs so that patients with rare diseases can benefit as soon as possible.